4-fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical

US6617359B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Paulus Wohlfart · Frankfurt am Main, DE
• Teri Suzuki · Tucson, US
• Ramalinga Dharanipragada · Montgomery, US
• Alena Safarova · Bound Brook, US
• Armin Walser · Tucson, US
• Hartmut Strobel · Liederbach, DE

Key dates

• Filing date: Feb 13, 2002
• Grant date: Sep 9, 2003
• Expiry date: Feb 13, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2602/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I) to the said mammal. The compound (I) can be used for the therapy and prophylaxis of cardiovascular diseases like stable and unstable angina pectoris, Prinzmetal angina (spasm), acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease PAOD, atherosclerosis, restenosis, endothelial damage after PTCA, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, and the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives, the therapy and prophylaxis of diabetes and diabetes complications (nephropathy, retinopathy), angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, restricted memory performance or a restricted ability to learn.